Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Alternative Sunitinib Schedules

PURPOSE: To identify sunitinib alternative schedules (AS) that maintained dose intensity while decreasing adverse events (AEs) in patients with metastatic renal cell cancer (mRCC), and to determine impact of AS on clinical outcomes. PATIENTS AND METHODS: A retrospective review of patients ≥ 18 yr of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Atkinson, Bradley J., Kalra, Sarathi, Wang, Xuemei, Bathala, Tharakeswara, Corn, Paul, Tannir, Nizar M., Jonasch, Eric
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2013
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4015627/
https://ncbi.nlm.nih.gov/pubmed/24018239
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.juro.2013.08.090
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge